Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.

Voriconazole may increase risk for squamous cell carcinoma in allogeneic HCT patients

09 Oct 2017

Use of voriconazole appears to increase the risk specifically for squamous cell carcinoma (SCC) in the allogeneic haematopoietic cell transplantation (HCT) population, according to a recent study.

To examine the effect of voriconazole on the risk for nonmelanoma skin cancer (NMSC), including SCC and basal cell carcinoma, researchers conducted a retrospective cohort study involving 1,220 individuals who had undergone allogeneic HCT and 1,418 who had undergone autologous HCT. Voriconazole exposure and other known risk factors for NMSC were included in multivariate analysis.

Multivariate analyses revealed that using voriconazole elevated the risk for NMSC (hazard ratio [HR], 1.82; 95 percent CI, 1.13 to 2.91) among patients who had undergone allogeneic HCT, particularly for SCC (HR, 2.25; 1.30 to 3.89). In patients who had undergone autologous HCT, using voriconazole did not contribute to an increased risk for NMSC.

In an earlier study, Wojenski and colleagues identified cumulative days of voriconazole use as a predictor of SCC development following allogeneic HCT. This information, according to them, may help guide appropriate antifungal use in this patient population. [Transpl Infect Dis 2015;17:250-8]

Meanwhile, a study by Boast and colleagues on voriconazole dosing and therapeutic drug monitoring (TDM) in children found a significant intra- and interindividual variability in voriconazole concentrations in children, particularly those <6 years of age, which warranted repeated TDM throughout treatment. The authors also recommended standardized guidelines for TDM and dose adjustment in children. [J Antimicrob Chemother 2016;71:2031-6]

The current study is limited by its retrospective design, according to researchers, adding that voriconazole has previously been tied to an increased risk for cutaneous SCC in solid organ transplant recipients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.